| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A controlled trial of renal denervation for resistant hypertension.
|
N Engl J Med
|
2014
|
14.22
|
|
2
|
Clinical end points in coronary stent trials: a case for standardized definitions.
|
Circulation
|
2007
|
10.31
|
|
3
|
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
|
N Engl J Med
|
2012
|
8.19
|
|
4
|
Diagnostic accuracy of fractional flow reserve from anatomic CT angiography.
|
JAMA
|
2012
|
6.96
|
|
5
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
J Am Coll Cardiol
|
2011
|
6.35
|
|
6
|
Percutaneous repair or surgery for mitral regurgitation.
|
N Engl J Med
|
2011
|
5.78
|
|
7
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Circulation
|
2011
|
5.09
|
|
8
|
Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models.
|
Circulation
|
2007
|
4.58
|
|
9
|
Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study.
|
J Am Coll Cardiol
|
2012
|
3.01
|
|
10
|
Nonemergency PCI at hospitals with or without on-site cardiac surgery.
|
N Engl J Med
|
2013
|
2.98
|
|
11
|
Lack of association between migraine headache and patent foramen ovale: results of a case-control study.
|
Circulation
|
2010
|
2.88
|
|
12
|
Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study.
|
Circulation
|
2009
|
2.02
|
|
13
|
Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness.
|
J Am Coll Cardiol
|
2013
|
2.01
|
|
14
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Circulation
|
2011
|
1.99
|
|
15
|
Coronary artery spatial distribution of acute myocardial infarction occlusions.
|
Circulation
|
2004
|
1.96
|
|
16
|
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice.
|
Arch Intern Med
|
2012
|
1.89
|
|
17
|
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.
|
Lancet
|
2012
|
1.80
|
|
18
|
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
|
J Am Coll Cardiol
|
2010
|
1.80
|
|
19
|
A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience.
|
JACC Cardiovasc Interv
|
2009
|
1.76
|
|
20
|
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
|
JACC Cardiovasc Interv
|
2011
|
1.75
|
|
21
|
Gangliosides as components of lipid membrane domains.
|
Glycobiology
|
2006
|
1.71
|
|
22
|
Saphenous vein graft intervention.
|
JACC Cardiovasc Interv
|
2011
|
1.69
|
|
23
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Catheter Cardiovasc Interv
|
2012
|
1.65
|
|
24
|
European Registry of Carotid Artery Stenting: results from a prospective registry of eight high volume EUROPEAN institutions.
|
Catheter Cardiovasc Interv
|
2012
|
1.61
|
|
25
|
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
|
JACC Cardiovasc Interv
|
2009
|
1.61
|
|
26
|
Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients.
|
Circulation
|
2008
|
1.59
|
|
27
|
N-glycolyl GM1 ganglioside as a receptor for simian virus 40.
|
J Virol
|
2007
|
1.59
|
|
28
|
Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy.
|
Circulation
|
2013
|
1.58
|
|
29
|
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
|
J Am Coll Cardiol
|
2006
|
1.56
|
|
30
|
Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.
|
J Am Coll Cardiol
|
2008
|
1.48
|
|
31
|
Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.
|
Circ Cardiovasc Interv
|
2012
|
1.46
|
|
32
|
Long-term clinical outcomes following drug-eluting or bare-metal stent placement in patients with severely reduced GFR: Results of the Massachusetts Data Analysis Center (Mass-DAC) State Registry.
|
Am J Kidney Dis
|
2010
|
1.46
|
|
33
|
Location of acute coronary artery thromboses in patients with and without chronic kidney disease.
|
Kidney Int
|
2008
|
1.44
|
|
34
|
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents.
|
J Am Coll Cardiol
|
2005
|
1.43
|
|
35
|
Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results.
|
Catheter Cardiovasc Interv
|
2010
|
1.42
|
|
36
|
Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.
|
JACC Cardiovasc Interv
|
2011
|
1.42
|
|
37
|
Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies.
|
Catheter Cardiovasc Interv
|
2014
|
1.40
|
|
38
|
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
|
JACC Cardiovasc Interv
|
2009
|
1.39
|
|
39
|
3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
|
JACC Cardiovasc Interv
|
2008
|
1.39
|
|
40
|
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.
|
Catheter Cardiovasc Interv
|
2015
|
1.37
|
|
41
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
42
|
Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains.
|
Chem Rev
|
2006
|
1.33
|
|
43
|
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.
|
BMJ
|
2013
|
1.32
|
|
44
|
Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
|
JACC Cardiovasc Interv
|
2013
|
1.28
|
|
45
|
2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.
|
J Am Coll Cardiol
|
2015
|
1.26
|
|
46
|
Rationale and design of the DeFACTO (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic AngiOgraphy) study.
|
J Cardiovasc Comput Tomogr
|
2011
|
1.23
|
|
47
|
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
|
JACC Cardiovasc Interv
|
2013
|
1.22
|
|
48
|
Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
|
JACC Cardiovasc Interv
|
2009
|
1.20
|
|
49
|
Ceramide and sphingomyelin species of fibroblasts and neurons in culture.
|
J Lipid Res
|
2006
|
1.19
|
|
50
|
A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial.
|
JACC Cardiovasc Interv
|
2008
|
1.15
|
|
51
|
Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients.
|
Am J Kidney Dis
|
2007
|
1.14
|
|
52
|
The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients.
|
Am Heart J
|
2006
|
1.13
|
|
53
|
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Catheter Cardiovasc Interv
|
2011
|
1.13
|
|
54
|
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
|
JACC Cardiovasc Interv
|
2009
|
1.11
|
|
55
|
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
|
J Am Coll Cardiol
|
2016
|
1.08
|
|
56
|
The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils.
|
J Exp Med
|
2013
|
1.06
|
|
57
|
Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
|
J Am Coll Cardiol
|
2007
|
1.06
|
|
58
|
A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
1.01
|
|
59
|
Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry.
|
JACC Cardiovasc Interv
|
2009
|
1.01
|
|
60
|
Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention.
|
Circ Cardiovasc Interv
|
2012
|
1.01
|
|
61
|
Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
|
JACC Cardiovasc Interv
|
2010
|
1.01
|
|
62
|
Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
|
Circulation
|
2011
|
1.00
|
|
63
|
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
|
JACC Cardiovasc Interv
|
2009
|
1.00
|
|
64
|
Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry.
|
Circ Cardiovasc Interv
|
2010
|
0.99
|
|
65
|
Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
|
Circulation
|
2008
|
0.98
|
|
66
|
Involvement of very long fatty acid-containing lactosylceramide in lactosylceramide-mediated superoxide generation and migration in neutrophils.
|
Glycoconj J
|
2007
|
0.98
|
|
67
|
Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention.
|
J Am Heart Assoc
|
2013
|
0.98
|
|
68
|
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.
|
J Am Coll Cardiol
|
2011
|
0.96
|
|
69
|
Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study.
|
Catheter Cardiovasc Interv
|
2007
|
0.94
|
|
70
|
Rationale and design of the HeartFlowNXT (HeartFlow analysis of coronary blood flow using CT angiography: NeXt sTeps) study.
|
J Cardiovasc Comput Tomogr
|
2013
|
0.94
|
|
71
|
Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale.
|
Stroke
|
2010
|
0.92
|
|
72
|
Lyn-coupled LacCer-enriched lipid rafts are required for CD11b/CD18-mediated neutrophil phagocytosis of nonopsonized microorganisms.
|
J Leukoc Biol
|
2007
|
0.92
|
|
73
|
The conundrum of late and very late stent thrombosis following drug-eluting stent implantation.
|
Curr Opin Cardiol
|
2007
|
0.92
|
|
74
|
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
|
J Thorac Cardiovasc Surg
|
2016
|
0.89
|
|
75
|
Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
|
JACC Cardiovasc Interv
|
2009
|
0.89
|
|
76
|
Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo.
|
J Leukoc Biol
|
2008
|
0.89
|
|
77
|
Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.
|
EuroIntervention
|
2010
|
0.89
|
|
78
|
EVEREST II randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure.
|
J Thorac Cardiovasc Surg
|
2012
|
0.88
|
|
79
|
Causes of short-term readmission after percutaneous coronary intervention.
|
Circ Cardiovasc Interv
|
2014
|
0.88
|
|
80
|
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
|
JACC Cardiovasc Interv
|
2013
|
0.86
|
|
81
|
Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients.
|
Stroke
|
2012
|
0.86
|
|
82
|
Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids.
|
J Lipid Res
|
2010
|
0.85
|
|
83
|
Why we still need randomized trials to compare effectiveness.
|
N Engl J Med
|
2012
|
0.84
|
|
84
|
Statistical analysis of noncommensurate multiple outcomes.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.84
|
|
85
|
Drug-eluting stents in the elderly.
|
Curr Treat Options Cardiovasc Med
|
2010
|
0.84
|
|
86
|
Choosing methods to minimize confounding in observational studies: do the ends justify the means?
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.84
|
|
87
|
Effect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents.
|
Am J Cardiol
|
2010
|
0.83
|
|
88
|
Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials).
|
Am J Cardiol
|
2010
|
0.83
|
|
89
|
One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent.
|
Am J Cardiol
|
2013
|
0.83
|
|
90
|
Right ventricular perforation and pulmonary embolism with polymethylmethacrylate cement after percutaneous kyphoplasty.
|
Circulation
|
2013
|
0.83
|
|
91
|
Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery?
|
J Am Coll Cardiol
|
2006
|
0.83
|
|
92
|
Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
|
Catheter Cardiovasc Interv
|
2013
|
0.82
|
|
93
|
A synthetic divalent cholera toxin glycocalix[4]arene ligand having higher affinity than natural GM1 oligosaccharide.
|
J Am Chem Soc
|
2005
|
0.82
|
|
94
|
Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents.
|
Circ Cardiovasc Interv
|
2009
|
0.82
|
|
95
|
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.
|
Heart
|
2013
|
0.81
|
|
96
|
Lipid rafts in neurodegeneration and neuroprotection.
|
Mol Neurobiol
|
2013
|
0.81
|
|
97
|
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
|
Circ Cardiovasc Interv
|
2011
|
0.81
|
|
98
|
Studies of drug-eluting stents: to each his own?
|
Circulation
|
2008
|
0.81
|
|
99
|
Instrumental variable analysis to compare effectiveness of stents in the extremely elderly.
|
Circ Cardiovasc Qual Outcomes
|
2013
|
0.81
|
|
100
|
Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
|
Circ Cardiovasc Interv
|
2010
|
0.80
|
|
101
|
Interactions between gangliosides and proteins in the exoplasmic leaflet of neuronal plasma membranes: a study performed with a tritium-labeled GM1 derivative containing a photoactivable group linked to the oligosaccharide chain.
|
Glycoconj J
|
2004
|
0.80
|
|
102
|
Modulation of cell functions by glycosphingolipid metabolic remodeling in the plasma membrane.
|
J Neurochem
|
2007
|
0.80
|
|
103
|
Nonculprit lesions--or guilty by association.
|
N Engl J Med
|
2013
|
0.80
|
|
104
|
Reply: Analysis of Dual Antiplatelet Therapy.
|
J Am Coll Cardiol
|
2015
|
0.79
|
|
105
|
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.
|
Am Heart J
|
2009
|
0.79
|
|
106
|
Photoactivable sphingosine as a tool to study membrane microenvironments in cultured cells.
|
J Lipid Res
|
2009
|
0.79
|
|
107
|
Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
|
EuroIntervention
|
2013
|
0.78
|
|
108
|
Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program.
|
EuroIntervention
|
2016
|
0.78
|
|
109
|
Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data.
|
Annu Rev Med
|
2010
|
0.78
|
|
110
|
Antiplatelet therapy after coronary stenting.
|
Curr Treat Options Cardiovasc Med
|
2013
|
0.78
|
|
111
|
Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped?
|
Curr Cardiol Rep
|
2006
|
0.77
|
|
112
|
Ceramides as possible nutraceutical compounds: characterization of the ceramides of the Moro blood orange ( Citrus sinensis ).
|
J Agric Food Chem
|
2012
|
0.77
|
|
113
|
Role of gangliosides and plasma membrane-associated sialidase in the process of cell membrane organization.
|
Adv Exp Med Biol
|
2011
|
0.77
|
|
114
|
Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists.
|
Clin Cardiol
|
2014
|
0.77
|
|
115
|
Gangliosides as regulators of cell signaling: ganglioside-protein interactions or ganglioside-driven membrane organization?
|
J Neurochem
|
2013
|
0.77
|
|
116
|
Effects of atrial fibrillation on treatment of mitral regurgitation in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized trial.
|
J Am Coll Cardiol
|
2012
|
0.77
|
|
117
|
Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.
|
Am Heart J
|
2012
|
0.76
|
|
118
|
Aberrant glycosphingolipid expression and membrane organization in tumor cells: consequences on tumor-host interactions.
|
Adv Exp Med Biol
|
2011
|
0.76
|
|
119
|
CKD and coronary collateral supply in individuals undergoing coronary angiography after myocardial infarction.
|
Clin J Am Soc Nephrol
|
2012
|
0.76
|
|
120
|
Optimal timing of noncardiac surgery after stents.
|
Circulation
|
2012
|
0.75
|
|
121
|
Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study.
|
J Interv Cardiol
|
2013
|
0.75
|
|
122
|
PCI at hospitals with or without on-site cardiac surgery.
|
N Engl J Med
|
2013
|
0.75
|
|
123
|
Duration of dual antiplatelet therapy after drug-eluting stents.
|
N Engl J Med
|
2015
|
0.75
|
|
124
|
Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
125
|
Adherence to dual antiplatelet therapy after coronary stenting: a systematic review.
|
Clin Cardiol
|
2014
|
0.75
|
|
126
|
Letter by Kereiakes et al regarding article, "Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern".
|
Circulation
|
2007
|
0.75
|
|
127
|
Structure of the main ganglioside from the brain of Xenopus laevis.
|
Glycoconj J
|
2002
|
0.75
|
|
128
|
Effect of structural modifications of ganglioside GM2 on intra-molecular carbohydrate-to-carbohydrate interaction and enzymatic susceptibility.
|
Biochim Biophys Acta
|
2007
|
0.75
|
|
129
|
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
130
|
Relative spatial distributions of coronary artery bypass graft insertion and acute thrombosis: a model for protection from acute myocardial infarction.
|
Am Heart J
|
2010
|
0.75
|
|
131
|
An evidence-based approach to the use of drug-eluting stents in clinical practice.
|
Am Heart Hosp J
|
2004
|
0.75
|
|
132
|
Performance of the resolute zotarolimus-eluting stent in small vessels.
|
Catheter Cardiovasc Interv
|
2014
|
0.75
|
|
133
|
A practical route to long-chain non-natural α,ω-diamino acids.
|
Amino Acids
|
2012
|
0.75
|
|
134
|
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy).
|
Am J Cardiol
|
2010
|
0.75
|
|
135
|
Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug.
|
JACC Cardiovasc Interv
|
2017
|
0.75
|
|
136
|
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
|
Eur J Cardiothorac Surg
|
2017
|
0.75
|
|
137
|
Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease.
|
Clin Exp Nephrol
|
2012
|
0.75
|
|
138
|
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
|
Eur Heart J
|
2017
|
0.75
|
|
139
|
Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?
|
EuroIntervention
|
2009
|
0.75
|
|
140
|
Gangliosides and cell surface ganglioside glycohydrolases in the nervous system.
|
Adv Neurobiol
|
2014
|
0.75
|